Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study reveals dumping syndrome risk in babies after esophageal repair

NCT ID NCT02525705

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 42 infants who had surgery for a rare birth defect called esophageal atresia type III. Researchers gave the babies a sugary drink to see how often they developed dumping syndrome, a condition causing rapid blood sugar changes. The goal was to find out how common this problem is at 3.5 months of age.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oral glucose
What this could lead to
If successful, this study could help doctors better understand and monitor dumping syndrome in infants after esophageal surgery.
What could go wrong
This is a small, observational study with only 42 infants, so results may not apply to all cases. It measures frequency, not treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Jun 2011

Finished

Jan 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 14 weeks

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * New born less than 3.5 months or age corrected for premature new born * Weight ≥ 4, 150 kg * Esophageal atresia (EA) type III or IV * EA Surgery between May 2013 and June 2016 * Stop of prokinetic treatment \> 72 h before OGTT * Information and consent of parents * Patients with health insurance Exclusion Criteria: * Age \> 3.5 months * Weight \< 4.150 kg * Other types of EA * Dumping syndrom from other origin: microgastria, dysautonomia, small intestine surgery * Other pathology that can modify glycemia: neonatal diabete, hyperinsulinism * Treatment that can modify gastric motility: domperidone, erythromycin, baclofen that hasn't been stopped in the 72h before OGTT * Absence of consent * Patient judiciary protected * Simultaneous participation to another clinical trial * No health insurance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dumping syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dumping syndrome esophageal atresia hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dumping syndrome Oesophageal atresia

Contacts and locations

Locations

  • AP-HP, Hôpital Necker

    Paris, France

  • CHU Grenoble

    Grenoble, France

  • CHU Nantes

    Nantes, France

  • CHU Rouen

    Rouen, France

  • CHU Strasbourg

    Strasbourg, France

  • CHU Toulouse, Hôpital Enfant

    Toulouse, France

  • Hôpital Edouard Herriot,Unité d'Hépatogastroentérologie et Nutrition Pédiatriques

    Lyon, France

  • Hôpital Jeanne de Flandre CHRU

    Lille, France

  • Hôpital Pellegrin - Hôpital d'Enfants,

    Bordeaux, France

  • Hôpital Robert Debré ,Service de chirurgie viscérale et urologique

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.